A Prospective, Randomized, Controlled, Multicenter Study Comparing the Right Versus Left Thoracic Surgical Approaches for Locally Advanced Siewert II Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy
Sponsor study identifier
interventional
236
1 country
1
Study Start
July 1, 2022
Actual (reported)Primary Completion
July 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
July 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
To explore the 5-year overall survival (OS) of right versus left thoracic surgical approaches for patients with locally advanced Siewert II gastroesophageal junction adenocarcinoma treated by neoadjuvant chemotherapy
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 1, 2022
Actual (reported)July 12, 2024
Actual (reported)October 16, 2024
Actual (reported)July 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
July 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
OS rate
OS is defined as the time from randomization to death due to any cause.
5 years
DFS rate
3 years
pCR rate
1 month after resection
MPR rate
1 month after resection
Operative Complications
perioperative period
Neoadjuvant therapy+surgery+adjuvant therapy. Neoadjuvant therapy: chemotherapy with 2-4 cycles； Surgery: dissociate the stomach and operate the gastroesophagostomy and lower mediastinal lymphadenectomy by the right thoracic approach (right thoracic incision); Adjuvant therapy: perioperative chemotherapy with total 8 cycles (including neoadjuvant chemotherapy).
Neoadjuvant therapy+surgery+adjuvant therapy. Neoadjuvant therapy: chemotherapy with 2-4 cycles； Surgery: dissociate the stomach and operate the gastroesophagostomy and lower mediastinal lymphadenectomy by the left thoracic approach (including right thoracic and abdominal incision); Adjuvant therapy: perioperative chemotherapy with total 8 cycles (including neoadjuvant chemotherapy).
Right Versus Left Thoracic Surgical Approaches
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
First Submitted
July 12, 2024
First Posted
October 16, 2024
Study Start
July 1, 2022
Actual (reported)Primary Completion
July 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Classification of Adenocarcinoma of the Esophagogastric Junction
Contact the study team to confirm eligibility.
Study Completion
July 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 16, 2024
Record last verified: 2024-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: